Table 3. Efficacy – response rates.
|
Gemcitabine and Vinorelbine
|
Gemcitabine and Cisplatin
|
Gemcitabine and Capecitabine
|
|||||||
|---|---|---|---|---|---|---|---|---|---|
| N | % | 95% CI | N | % | 95% CI | N | % | 95% CI | |
| CR | 3 | 7.3 | 1.5–19.9 | 4 | 9.1 | 2.5–21.7 | 4 | 8.2 | 2.3–19.6 |
| PR | 13 | 31.7 | 18.1–48.1 | 17 | 38.6 | 24.4–54.5 | 13 | 26.5 | 15.0–41.1 |
| ORR | 16 | 39.0 | 24.2–55.5 | 21 | 47.7 | 32.5–63.3 | 17 | 34.7 | 21.7–49.6 |
| SD | 10 | 24.4 | 12.4–40.3 | 4 | 9.1 | 2.5–21.7 | 12 | 24.5 | 13.3–38.9 |
| PD | 11 | 26.8 | 14.2–42.9 | 11 | 25.0 | 13.2–40.3 | 12 | 24.5 | 13.3–38.9 |
| NE | 4 | 9.8 | 2.7–23.1 | 8 | 18.2 | 8.2–32.7 | 8 | 16.3 | 7.3–29.7 |
| All | 41 | 100.0 | 44 | 100.0 | 49 | 100.0 | |||
Abbreviations: CI=confidence interval; CR=complete remission; NE=not evaluable by Fishers exact test; ORR=overall response rate; PD=progressive disease; PR=partial response; SD=stable disease.